{"protocolSection": {"identificationModule": {"nctId": "NCT04046939", "orgStudyIdInfo": {"id": "KNS-760704-AS201"}, "organization": {"fullName": "Knopp Biosciences", "class": "INDUSTRY"}, "briefTitle": "Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma", "acronym": "EXHALE-1"}, "statusModule": {"statusVerifiedDate": "2023-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-08-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-03-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-07-30", "studyFirstSubmitQcDate": "2019-08-02", "studyFirstPostDateStruct": {"date": "2019-08-06", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-11-23", "resultsFirstSubmitQcDate": "2021-11-23", "resultsFirstPostDateStruct": {"date": "2021-12-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-04-11", "lastUpdatePostDateStruct": {"date": "2023-04-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Knopp Biosciences", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.", "detailedDescription": "One hundred subjects will receive study drug or matching placebo over 12 weeks of consecutive dosing. Following a short Run-in Period, eligible subjects will enter the Primary Assessment Period and receive twice-daily dosing of study drug or placebo for 12 weeks. Following 12 weeks of treatment, subjects will enter a 12-week Eosinophil Recovery Period. The primary endpoint for the study is the change in blood absolute eosinophil count from Baseline to Week 12."}, "conditionsModule": {"conditions": ["Eosinophilic Asthma", "Asthma"], "keywords": ["Eosinophilic Asthma", "Asthma", "dexpramipexole"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Four-arm parallel assignment", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 534, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "placebo BID", "type": "PLACEBO_COMPARATOR", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "37.5 mg BID dexpramipexole", "type": "ACTIVE_COMPARATOR", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.", "interventionNames": ["Drug: Dexpramipexole"]}, {"label": "75 mg BID dexpramipexole", "type": "ACTIVE_COMPARATOR", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.", "interventionNames": ["Drug: Dexpramipexole"]}, {"label": "150 mg BID dexpramipexole", "type": "ACTIVE_COMPARATOR", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.", "interventionNames": ["Drug: Dexpramipexole"]}], "interventions": [{"type": "DRUG", "name": "Dexpramipexole", "description": "dexpramipexole twice daily oral dosing for up to 12 weeks", "armGroupLabels": ["150 mg BID dexpramipexole", "37.5 mg BID dexpramipexole", "75 mg BID dexpramipexole"], "otherNames": ["KNS-760704", "BIIB050"]}, {"type": "DRUG", "name": "Placebo", "description": "placebo twice daily oral dosing for up to 12 weeks", "armGroupLabels": ["placebo BID"], "otherNames": ["PBO"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Blood Absolute Eosinophil Count From Baseline to Week 12", "description": "The primary endpoint of this study was the change in AEC from Baseline to Week 12 on a ratio scale. The analysis used a mixed effects model repeated-measures (MMRM) with terms for log10 transformed baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and log10 transformed baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the log10 transformed post-baseline value minus the log10 transformed baseline value. The estimates of Geometric LS Means and their ratios were obtained by back transforming the corresponding estimates of LS means and their differences to the original scale.", "timeFrame": "Baseline, 12 Weeks"}], "secondaryOutcomes": [{"measure": "Change in Pre-bronchodilator FEV1 (Liters) From Baseline to Week 12", "description": "FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "timeFrame": "Baseline, 12 Weeks"}, {"measure": "Change in Asthma Control Questionnaire (ACQ-6) Score From Baseline to Week 12", "description": "ACQ-6 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. The 6-point self-administered scale has items measuring asthma symptoms and rescue inhaler use. The ACQ score is the mean of the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). The original protocol planned to analyze the ACQ-7 score. As a result of FEV1 testing restrictions imposed on the study during the COVID-19 pandemic, the analysis was prospectively modified to the ACQ-6 score prior to database lock. The ACQ-6 is a validated questionnaire and is identical to the ACQ-7, with the exception of FEV1 data that is also utilized in the ACQ-7 questionnaire total score calculation.", "timeFrame": "Baseline, 12 Weeks"}, {"measure": "Change in Post-bronchodilator FEV1 From Baseline to Week 12", "description": "Post-bronchodilator FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation, after treatment with inhaled albuterol.", "timeFrame": "Baseline, 12 Weeks"}, {"measure": "Change in Quality of Life, as Measured by the Asthma Quality of Life Questionnaire (AQLQ) From Baseline to Week 12", "description": "The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma. The 32 questions in the AQLQ are divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.", "timeFrame": "Baseline, 12 Weeks"}, {"measure": "Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Hematology Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "timeFrame": "Immediately post-baseline up to Week 12"}, {"measure": "Number of Participants With Potentially Clinically Significant Blood Chemistry Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Blood Chemistry Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "timeFrame": "Immediately post-baseline up to Week 12"}, {"measure": "Number of Participants With Potentially Clinically Significant Urinalysis Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Urinalysis Results (glycosuria, ketonuria, or proteinuria) by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline urinalysis value in each treatment group. Patients are only counted once per criterion per laboratory test. The number of participants with potential clinical important urinalysis findings at any post-baseline visit were reported.", "timeFrame": "Immediately post-baseline up to Week 12"}, {"measure": "Number of Participants With Potentially Clinically Significant Vital Signs Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Vital Signs Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "timeFrame": "Immediately post-baseline up to Week 12"}, {"measure": "Number of Participants With Potentially Clinically Significant ECG Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant ECG Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "timeFrame": "Immediately post-baseline up to Week 12"}], "otherOutcomes": [{"measure": "Change in Nasal Eosinophil Peroxidase (Presented as Ratio to Protein) From Baseline to Week 12", "description": "The EPX:protein ratio was used to normalize the EPX for the quantity of sample, yielding the values in ng EPX per mg protein. The ratio of nasal Eosinophil Peroxidase to Protein is a biomarker for airway eosinophils. A lower ratio to Baseline represents a lowering in airway eosinophilia, which is a marker of successful drug therapy.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Blood Absolute Blood Basophil Count From Baseline to Week 12", "description": "The analysis used a mixed effects model repeated-measures MMRM with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value. Basophils were enumerated as part of the WBC automated differential performed by the Central Laboratory.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 12", "description": "FeNO is non-invasive biomarker of airway inflammation in asthma participants.", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female \u226518 and \\<75 years of age at the time of consent\n* Physician diagnosis of asthma for \u226512 months (relative to Baseline) based on Global Initiative for Asthma (GINA) 2018 Guidelines\n* Asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in combination with a long-acting \u03b22 agonist, on a stable dose for at least 1 month before Screening\n* Bronchodilator reversibility, as evidenced by \u226512% and \u2265200 mL improvement in FEV1 15 to 25 minutes following inhalation of albuterol at Screening\n* Pre-bronchodilator FEV1 \u226540% and \\<80% of predicted at Screening and Baseline\n* AEC \u22650.30 x10\\^9/L at the Screening visit\n* ACQ-7 \u22651.5 at Screening\n* Negative pregnancy test at Baseline\n* Adherence \u226585% with twice-daily placebo taken during the Run-in Period\n\nExclusion Criteria:\n\n* Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit\n* Treatment with systemic corticosteroids in the 8 weeks prior to Screening\n* Treatment with monoclonal antibody therapy, within 5-half-lives prior to Baseline\n* Treatment with selected drugs known to have a substantial risk of neutropenia\n* Absolute neutrophil count \\<2.0x10\\^9/L at Screening, or any documented history of absolute neutrophil count \\<2.0x10\\^9/L.\n* Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \\<60 mL/min/1.73m\\^2 at Screening\n* Clinically significant abnormal laboratory or ECG values\n* Other medically significant illness\n* Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening\n* Pregnant women or women breastfeeding\n* Currently taking pramipexole or other dopamine agonists", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "74 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Research Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Daytona Beach", "state": "Florida", "zip": "32117", "country": "United States", "geoPoint": {"lat": 29.21081, "lon": -81.02283}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33186", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33612", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33634", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Research Site", "city": "Winder", "state": "Georgia", "zip": "30680", "country": "United States", "geoPoint": {"lat": 33.99261, "lon": -83.72017}}, {"facility": "Research Site", "city": "Boise", "state": "Idaho", "zip": "83706", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Research Site", "city": "Farmington Hills", "state": "Michigan", "zip": "48336", "country": "United States", "geoPoint": {"lat": 42.48531, "lon": -83.37716}}, {"facility": "Research site", "city": "Plymouth", "state": "Minnesota", "zip": "55441", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "New Brunswick", "state": "New Jersey", "zip": "08901", "country": "United States", "geoPoint": {"lat": 40.48622, "lon": -74.45182}}, {"facility": "Research Site", "city": "Corning", "state": "New York", "zip": "14830", "country": "United States", "geoPoint": {"lat": 42.14285, "lon": -77.05469}}, {"facility": "Research Site", "city": "New Hyde Park", "state": "New York", "zip": "11042", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "Research Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Columbus", "state": "Ohio", "zip": "43235", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Research Site", "city": "Dublin", "state": "Ohio", "zip": "43016", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "zip": "97202", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15205", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Anderson", "state": "South Carolina", "zip": "29621", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"facility": "Research Site", "city": "North Charleston", "state": "South Carolina", "zip": "29406", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Research Site", "city": "Allen", "state": "Texas", "zip": "75013", "country": "United States", "geoPoint": {"lat": 33.10317, "lon": -96.67055}}, {"facility": "Research Site", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75240", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "zip": "79902", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 534 participants enrolled, 144 subjects received placebo treatment during the Run-in Period. Of those, 103 completed the Run-in Period, were eligible for randomization, and entered the Primary Assessment Period.", "groups": [{"id": "FG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "FG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "FG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "FG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "periods": [{"title": "Screening Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "534"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Received Placebo During Run-In Period", "achievements": [{"groupId": "FG000", "numSubjects": "144"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "103"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "431"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Primary Assessment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "26"}, {"groupId": "FG003", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "24"}, {"groupId": "FG003", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Eosinophil Recovery Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "24"}, {"groupId": "FG003", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "24"}, {"groupId": "FG003", "numSubjects": "27"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population: all subjects who were randomized and received at least 1 dose of study drug (placebo, dexpramipexole) during the Primary Assessment Period.", "groups": [{"id": "BG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "BG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "BG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "BG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "103"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.8", "spread": "12.89"}, {"groupId": "BG001", "value": "46.6", "spread": "13.41"}, {"groupId": "BG002", "value": "44.5", "spread": "15.46"}, {"groupId": "BG003", "value": "44.6", "spread": "12.53"}, {"groupId": "BG004", "value": "45.3", "spread": "13.42"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "<50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "62"}]}]}, {"title": "50 to 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "33"}]}]}, {"title": ">65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "54"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "49"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "11"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "25"}, {"groupId": "BG004", "value": "92"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "4"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "20"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "76"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}]}]}]}, {"title": "Body mass index", "description": "Body mass index (kg/m\\^2) = body weight (kg) / height (m\\^2)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.31", "spread": "12.749"}, {"groupId": "BG001", "value": "31.73", "spread": "7.379"}, {"groupId": "BG002", "value": "33.44", "spread": "10.690"}, {"groupId": "BG003", "value": "32.13", "spread": "7.040"}, {"groupId": "BG004", "value": "32.95", "spread": "9.738"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Blood Absolute Eosinophil Count From Baseline to Week 12", "description": "The primary endpoint of this study was the change in AEC from Baseline to Week 12 on a ratio scale. The analysis used a mixed effects model repeated-measures (MMRM) with terms for log10 transformed baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and log10 transformed baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the log10 transformed post-baseline value minus the log10 transformed baseline value. The estimates of Geometric LS Means and their ratios were obtained by back transforming the corresponding estimates of LS means and their differences to the original scale.", "populationDescription": "The efficacy population will be a modified intent-to-treat sample and consist of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization AEC evaluation.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio to baseline", "timeFrame": "Baseline, 12 Weeks", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.8980", "spread": "1.26"}, {"groupId": "OG001", "value": "0.4031", "spread": "1.28"}, {"groupId": "OG002", "value": "0.3056", "spread": "1.27"}, {"groupId": "OG003", "value": "0.2051", "spread": "1.25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "<.0001", "pValueComment": "A closed hierarchical procedure testing dexpramipexole against placebo at Week 12 was used. (1) 150 mg BID for AEC (2) 75 mg BID for AEC (3) pooled 75 mg and 150 mg BID group for pre-bronchodilator FEV1; and (4) 37.5 mg BID for AEC.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Ratio to PBO of the ratios to baseline", "paramValue": "0.2283", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.121", "ciUpperLimit": "0.431", "estimateComment": "0.2283 represents the ratio of the 150 mg BID week 12 ratio to baseline (0.2051), compared to the PBO week 12 ratio to baseline (0.8980). This ratio of 0.2283 is equivalent to a -77.17% change compared to placebo at week 12."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0014", "pValueComment": "A closed hierarchical procedure testing dexpramipexole against placebo at Week 12 was used. (1) 150 mg BID for AEC (2) 75 mg BID for AEC (3) pooled 75 mg and 150 mg BID group for pre-bronchodilator FEV1; and (4) 37.5 mg BID for AEC.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Ratio to PBO of the ratios to baseline", "paramValue": "0.3403", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.177", "ciUpperLimit": "0.653", "estimateComment": "0.3403 represents the ratio of the 75 mg BID week 12 ratio to baseline (0.3056), compared to the PBO week 12 ratio to baseline (0.8980). This ratio of 0.3403 is equivalent to a -65.97% change compared to placebo at week 12."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0190", "pValueComment": "A closed hierarchical statistical testing was used. The previous endpoint in the hierarchy was not statistically significant. Therefore, this endpoint was not formally tested and is not considered statistically significant, despite a p-value \\<0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Ratio to PBO of the ratios to baseline", "paramValue": "0.4489", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.231", "ciUpperLimit": "0.874", "estimateComment": "0.4489 represents the ratio of the 37.5 mg BID week 12 ratio to baseline (0.4031) compared to the PBO week 12 ratio to baseline (0.8980). This ratio of 0.4489 is equivalent to a -55.11% change compared to placebo at week 12."}]}, {"type": "SECONDARY", "title": "Change in Pre-bronchodilator FEV1 (Liters) From Baseline to Week 12", "description": "FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "populationDescription": "The efficacy population will be a modified intent-to-treat sample and consist of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization FEV1 evaluation. Spirometry restrictions were put in place during the COVID-19 pandemic. Subjects who did not complete the Week 8 and Week 12 post dose assessments due to these restrictions were excluded from this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline, 12 Weeks", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG004", "title": "Combined 150 mg BID and 75 mg BID Arms", "description": "Following a 2-4 week placebo run-in, randomized subjects in this combined treatment group received 1 tablet of either 150 mg dexpramipexole twice daily for 12 weeks or 75 mg dexpramipexole trice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0700", "spread": "0.08329"}, {"groupId": "OG001", "value": "0.208", "spread": "0.08387"}, {"groupId": "OG002", "value": "0.0557", "spread": "0.07848"}, {"groupId": "OG003", "value": "0.247", "spread": "0.07769"}, {"groupId": "OG004", "value": "0.151", "spread": "0.05746"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "The combined 75 mg and 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4154", "pValueComment": "A closed hierarchical procedure testing dexpramipexole against placebo at Week 12 was used. (1) 150 mg BID for AEC (2) 75 mg BID for AEC (3) pooled 75 mg and 150 mg BID group for pre-bronchodilator FEV1; and (4) 37.5 mg BID for AEC.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.0814", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.116", "ciUpperLimit": "0.279", "estimateComment": "Estimate is the difference of the pooled 75 mg and 150 mg BID group from placebo in change in pre-bronchodilator FEV1 in liters from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement in lung function."}, {"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1174", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.177", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0456", "ciUpperLimit": "0.400", "estimateComment": "Estimate is the difference of the 150 mg BID group from the placebo group in the change in pre-bronchodilator FEV1 in liters from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement in lung function."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8998", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0143", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.240", "ciUpperLimit": "0.211", "estimateComment": "Estimate is the difference of the 75 mg BID group from the placebo group in the change in pre-bronchodilator FEV1 in liters from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement in lung function."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2425", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.138", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0950", "ciUpperLimit": "0.370", "estimateComment": "Estimate is the difference of the 37.5 mg BID group from the placebo group in the change in pre-bronchodilator FEV1 in liters from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement in lung function."}]}, {"type": "SECONDARY", "title": "Change in Asthma Control Questionnaire (ACQ-6) Score From Baseline to Week 12", "description": "ACQ-6 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. The 6-point self-administered scale has items measuring asthma symptoms and rescue inhaler use. The ACQ score is the mean of the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). The original protocol planned to analyze the ACQ-7 score. As a result of FEV1 testing restrictions imposed on the study during the COVID-19 pandemic, the analysis was prospectively modified to the ACQ-6 score prior to database lock. The ACQ-6 is a validated questionnaire and is identical to the ACQ-7, with the exception of FEV1 data that is also utilized in the ACQ-7 questionnaire total score calculation.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consist of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization evaluation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, 12 Weeks", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.391", "spread": "0.1866"}, {"groupId": "OG001", "value": "-0.419", "spread": "0.1974"}, {"groupId": "OG002", "value": "-0.437", "spread": "0.1924"}, {"groupId": "OG003", "value": "-0.655", "spread": "0.1803"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3059", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.264", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.772", "ciUpperLimit": "0.245", "estimateComment": "Estimate is the difference of the 150 mg BID dexpramipexole group compared to the placebo group in change in ACQ-6 score from Baseline to Week 12 (end of primary treatment period). A negative value indicates improvement of asthma symptoms."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8642", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0457", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.575", "ciUpperLimit": "0.484", "estimateComment": "Estimate is the difference of the 75 mg BID dexpramipexole group compared to the placebo group in change in ACQ-6 score from Baseline to Week 12 (end of primary treatment period). A negative value indicates improvement of asthma symptoms."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9182", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0276", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.560", "ciUpperLimit": "0.505", "estimateComment": "Estimate is the difference of the 37.5 mg BID dexpramipexole group compared to the placebo group in change in ACQ-6 score from Baseline to Week 12 (end of primary treatment period). A negative value indicates improvement of asthma symptoms."}]}, {"type": "SECONDARY", "title": "Change in Post-bronchodilator FEV1 From Baseline to Week 12", "description": "Post-bronchodilator FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation, after treatment with inhaled albuterol.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consist of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization evaluation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline, 12 Weeks", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "22"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00546", "spread": "0.07208"}, {"groupId": "OG001", "value": "0.0932", "spread": "0.07455"}, {"groupId": "OG002", "value": "-0.000717", "spread": "0.06977"}, {"groupId": "OG003", "value": "0.176", "spread": "0.07182"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "An ANCOVA analysis was performed comparing the 150 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0716", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.181", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0163", "ciUpperLimit": "0.378", "estimateComment": "Estimate the difference of the 150 mg BID Dexpramipexole group from placebo in change in post-bronchodilator FEV1 from Baseline to Week 12 (end of primary treatment period) in liters. A positive value indicates improvement in lung function."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "An ANCOVA analysis was performed comparing the 75 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9619", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.00474", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.192", "ciUpperLimit": "0.202", "estimateComment": "Estimate the difference of the 75 mg BID Dexpramipexole group from placebo in change in post-bronchodilator FEV1 from Baseline to Week 12 (end of primary treatment period) in liters. A positive value indicates improvement in lung function."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "An ANCOVA analysis was performed comparing the 37.5 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3368", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.0987", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.105", "ciUpperLimit": "0.302", "estimateComment": "Estimate the difference of the 37.5 mg BID Dexpramipexole group from placebo in change in post-bronchodilator FEV1 from Baseline to Week 12 (end of primary treatment period) in liters. A positive value indicates improvement in lung function."}]}, {"type": "SECONDARY", "title": "Change in Quality of Life, as Measured by the Asthma Quality of Life Questionnaire (AQLQ) From Baseline to Week 12", "description": "The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma. The 32 questions in the AQLQ are divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consist of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization evaluation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, 12 Weeks", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.376", "spread": "0.1999"}, {"groupId": "OG001", "value": "0.531", "spread": "0.2112"}, {"groupId": "OG002", "value": "0.312", "spread": "0.2055"}, {"groupId": "OG003", "value": "0.584", "spread": "0.1979"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "An ANCOVA analysis was performed comparing the 150 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4512", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.208", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.338", "ciUpperLimit": "0.755", "estimateComment": "Estimate the difference in the 150 mg BID dexpramipexole group from the placebo group in the change in AQLQ score from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement of asthma symptoms."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "An ANCOVA analysis was performed comparing the 75 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8214", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0642", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.627", "ciUpperLimit": "0.499", "estimateComment": "Estimate the difference in the 75 mg BID dexpramipexole group from the placebo group in the change in AQLQ score from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement of asthma symptoms."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "An ANCOVA analysis was performed comparing the 37.5 mg BID dexpramipexole group to placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5894", "pValueComment": "For secondary endpoints which were not key secondary endpoints, no adjustment for multiple testing was used and p \\<0.05 was used for statistical significance.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.154", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.411", "ciUpperLimit": "0.720", "estimateComment": "Estimate the difference in the 37.5 mg BID dexpramipexole group from the placebo group in the change in AQLQ score from Baseline to Week 12 (end of primary treatment period). A positive value indicates improvement of asthma symptoms."}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Hematology Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "populationDescription": "The safety population includes all subjects who were randomized and received at least one dose of study drug during the primary treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately post-baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Eosinophils >1.6 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Basophils >1.6 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Erythrocytes \u22643.5 x 10^12/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "Erythrocytes \u22656.4 x 10^12/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Hematocrit \u226432% - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Hematocrit \u226554% - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Hematocrit \u226437% - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Hematocrit \u226560% - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Hemoglobin \u22649.5 g/dL - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Hemoglobin \u226517.5 g/dL - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Hemoglobin \u226411.5 g/dL - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Hemoglobin \u226519.0 g/dL - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Leukocytes <3.0 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Leukocytes \u226516 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Lymphocytes <0.8 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Lymphocytes >12 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Monocytes >2.5 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Neutrophils <1.5 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Neutrophils \u226513.5 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Platelets \u226475 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Platelets \u2265700 x 10^9/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Blood Chemistry Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Blood Chemistry Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "populationDescription": "The safety population includes all subjects who were randomized and received at least one dose of study drug during the primary treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately post-baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "ALT \u2265 3 x ULN", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Albumin \u2264 2.5 g/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Alkaline Phosphatase \u2265 1.5 x ULN", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "AST \u2265 3 x ULN", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Bicarbonate \u2264 16 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Bicarbonate \u2265 35 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Bilirubin > 2 X ULN and (ALT or AST \u2265 3 X ULN)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Bilirubin \u2265 1.5 x ULN", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Calcium \u2264 8 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Calcium \u2265 12 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Chloride \u2264 90 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Chloride \u2265 118 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Creatinine \u2265 2 mg/dL - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Creatinine \u2265 2 mg/dL - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Glucose \u2264 39.6 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Glucose \u2265 175 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Magnesium \u2264 1.2 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Magnesium \u2265 2.9 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Phosphate \u2264 1.86 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Phosphate \u2265 5.27 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Potassium \u2264 3 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Potassium \u2265 6 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Protein [Serum] \u2264 4.5 g/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Protein [Serum] \u2265 10 g/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Sodium \u2264 126 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Sodium \u2265 156 mEq/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Urate \u2265 8.5 mg/dL - Females", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Urate \u2265 10.5 mg/dL - Males", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Urea Nitrogen \u2265 30 mg/dL", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Urinalysis Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Urinalysis Results (glycosuria, ketonuria, or proteinuria) by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline urinalysis value in each treatment group. Patients are only counted once per criterion per laboratory test. The number of participants with potential clinical important urinalysis findings at any post-baseline visit were reported.", "populationDescription": "The safety population includes all subjects who were randomized and received at least one dose of study drug during the primary treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately post-baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "glycosuria (glucose in urine ++++)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "ketonuria (ketones in urine \u2265 ++++)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "proteinuria (protein in urine \u2265 ++)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Vital Signs Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant Vital Signs Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "populationDescription": "The safety population includes all subjects who were randomized and received at least one dose of study drug during the primary treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately post-baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Systolic blood pressure: >180 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Systolic blood pressure: Increase >40 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Systolic blood pressure: <90 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Systolic blood pressure: Decrease >30 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Diastolic blood pressure: >105 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Diastolic blood pressure: Increase >30 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Diastolic blood pressure: <50 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Diastolic blood pressure: Decrease >20 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Pulse: >120 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Pulse: Increase >30 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Pulse: <50 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Pulse: Decrease >20 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Temperature: >38.5\u00b0C and an increase \u22651\u00b0C", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Body weight: Increase \u22657% from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Body weight: Decrease \u22657% from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant ECG Results by Treatment Group Post Randomization Through Week 12", "description": "Number of Participants with Potentially Clinically Significant ECG Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.", "populationDescription": "The safety population includes all subjects who were randomized and received at least one dose of study drug during the primary treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately post-baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Heart Rate >120 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Heart Rate Increase from Baseline >30 bpm", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "QT Interval: >450 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QT Interval: >480 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QT Interval: >500 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QT Interval: Increase from Baseline >30 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QT Interval: Increase from Baseline >60 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QTcF Interval: >450 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QTcF Interval: >480 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QTcF Interval: >500 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QTcF Interval: Increase from Baseline >30 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "QTcF Interval: Increase from Baseline >60 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Change from Baseline in PR >25% and PR value >220 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Change from Baseline in QRS >25% and QRS value >110 ms", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Nasal Eosinophil Peroxidase (Presented as Ratio to Protein) From Baseline to Week 12", "description": "The EPX:protein ratio was used to normalize the EPX for the quantity of sample, yielding the values in ng EPX per mg protein. The ratio of nasal Eosinophil Peroxidase to Protein is a biomarker for airway eosinophils. A lower ratio to Baseline represents a lowering in airway eosinophilia, which is a marker of successful drug therapy.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consists of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who had both Baseline (non-zero) and Week 12 values.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ratio to baseline", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.833", "lowerLimit": "0.258", "upperLimit": "2.99"}, {"groupId": "OG001", "value": "0.645", "lowerLimit": "0.275", "upperLimit": "1.18"}, {"groupId": "OG002", "value": "0.174", "lowerLimit": "0", "upperLimit": "0.708"}, {"groupId": "OG003", "value": "0.110", "lowerLimit": "0", "upperLimit": "0.943"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo at Week 12 using a Wilcoxon rank sum test.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0196", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75mg BID dexpramipexole group was compared to placebo at Week 12 using a Wilcoxon rank sum test.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0207", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo at Week 12 using a Wilcoxon rank sum test.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5399", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Blood Absolute Blood Basophil Count From Baseline to Week 12", "description": "The analysis used a mixed effects model repeated-measures MMRM with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value. Basophils were enumerated as part of the WBC automated differential performed by the Central Laboratory.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consists of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization evaluation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cells (10*9/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00439", "spread": "0.006323"}, {"groupId": "OG001", "value": "-0.00655", "spread": "0.006674"}, {"groupId": "OG002", "value": "-0.0250", "spread": "0.006487"}, {"groupId": "OG003", "value": "-0.0277", "spread": "0.006082"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0084", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0233", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0405", "ciUpperLimit": "-0.00613", "estimateComment": "Estimate is the difference of the 150 mg BID group from the placebo group in the change absolute basophil count (automated differential) from Baseline to Week 12 (end of primary treatment period). A negative value represents fewer basophils."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0237", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0206", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0384", "ciUpperLimit": "-0.00281", "estimateComment": "Estimate is the difference of the 75 mg BID group from the placebo group in the change absolute basophil count (automated differential) from Baseline to Week 12 (end of primary treatment period). A negative value represents fewer basophils."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8140", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.00215", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0203", "ciUpperLimit": "0.0160", "estimateComment": "Estimate is the difference of the 37.5 mg BID group from the placebo group in the change absolute basophil count (automated differential) from Baseline to Week 12 (end of primary treatment period). A negative value represents fewer basophils."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 12", "description": "FeNO is non-invasive biomarker of airway inflammation in asthma participants.", "populationDescription": "The efficacy population was a modified intent-to-treat sample and consists of all subjects in the safety population (all subjects who were randomized and received at least one dose of randomized study drug) and who have at least one post-randomization evaluation.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "parts per billion", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo BID", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.\n\nPlacebo: placebo twice daily oral dosing for up to 12 weeks"}, {"id": "OG001", "title": "37.5 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG002", "title": "75 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}, {"id": "OG003", "title": "150 mg BID Dexpramipexole", "description": "Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.\n\nDexpramipexole: dexpramipexole twice daily oral dosing for up to 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.38", "spread": "4.6447"}, {"groupId": "OG001", "value": "-6.79", "spread": "4.7849"}, {"groupId": "OG002", "value": "-3.14", "spread": "4.3651"}, {"groupId": "OG003", "value": "-4.86", "spread": "4.2175"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "The 150 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1886", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.6", "ciUpperLimit": "4.13", "estimateComment": "Estimate is the difference of the 150 mg BID group from the placebo group in the change in FeNO from Baseline to Week 12 in liters. In eosinophilic asthma, a lower FeNO indicates less eosinophilic inflammation of the airway than a higher value."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 75mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3061", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.1", "ciUpperLimit": "6.08", "estimateComment": "Estimate is the difference of the 75 mg BID group from the placebo group in the change in FeNO from Baseline to Week 12 in liters. In eosinophilic asthma, a lower FeNO indicates less eosinophilic inflammation of the airway than a higher value."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The 37.5 mg BID dexpramipexole group was compared to placebo using a mixed effects model repeated-measures (MMRM) with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1294", "pValueComment": "No adjustment for multiple testing of exploratory endpoints was used.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.4", "ciUpperLimit": "3.04", "estimateComment": "Estimate is the difference of the 37.5 mg BID group from the placebo group in the change in FeNO from Baseline to Week 12 in liters. In eosinophilic asthma, a lower FeNO indicates less eosinophilic inflammation of the airway than a higher value."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Placebo Run-in Period = from enrollment to Randomization (2-4 weeks); Primary Assessment Period = from Randomization through the Week 12 visit, plus 30 days following the last dose; Eosinophil Recovery Period = all visits occurring from 30 days following the last dose through the end of study (Week 24 post-Randomization)", "eventGroups": [{"id": "EG000", "title": "Screening Period", "description": "All subjects who signed informed consent and entered the Primary Assessment Period", "deathsNumAffected": 0, "deathsNumAtRisk": 103, "seriousNumAffected": 0, "seriousNumAtRisk": 103, "otherNumAffected": 6, "otherNumAtRisk": 103}, {"id": "EG001", "title": "Primary Assessment Period: Placebo BID", "description": "Following the 2-4 week placebo Run-in Period, randomized subjects continued to receive 1 tablet placebo twice daily for 12 weeks during the Primary Assessment Period.\n\nPlacebo: 1 placebo tablet twice daily", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 9, "otherNumAtRisk": 27}, {"id": "EG002", "title": "Primary Assessment Period: 37.5 mg BID", "description": "Following the 2-4 week placebo Run-in Period, randomized subjects received 1 tablet dexpramipexole 37.5 mg twice daily for 12 weeks during the Primary Assessment Period.\n\nDexpramipexole: 1 dexpramipexole tablet twice daily", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 0, "seriousNumAtRisk": 22, "otherNumAffected": 7, "otherNumAtRisk": 22}, {"id": "EG003", "title": "Primary Assessment Period: 75 mg BID", "description": "Following the 2-4 week placebo Run-in Period, randomized subjects received 1 tablet dexpramipexole 75 mg twice daily for 12 weeks during the Primary Assessment Period.\n\nDexpramipexole: 1 dexpramipexole tablet twice daily", "deathsNumAffected": 0, "deathsNumAtRisk": 26, "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 12, "otherNumAtRisk": 26}, {"id": "EG004", "title": "Primary Assessment Period: 150 mg BID", "description": "Following the 2-4 week placebo Run-in Period, randomized subjects received 1 tablet dexpramipexole 150 mg twice daily for 12 weeks during the Primary Assessment Period.\n\nDexpramipexole: 1 dexpramipexole tablet twice daily", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 12, "otherNumAtRisk": 28}, {"id": "EG005", "title": "Eosinophil Recovery Period: Assigned to Placebo BID During Primary Assessment Period", "description": "Following the Primary Assessment Period, subjects were followed within their randomized treatment group", "deathsNumAffected": 0, "deathsNumAtRisk": 25, "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 2, "otherNumAtRisk": 25}, {"id": "EG006", "title": "Eosinophil Recovery Period: Assigned to 37.5 mg BID During Primary Assessment Period", "description": "Following the Primary Assessment Period, subjects were followed within their randomized treatment group", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 0, "seriousNumAtRisk": 22, "otherNumAffected": 3, "otherNumAtRisk": 22}, {"id": "EG007", "title": "Eosinophil Recovery Period: Assigned to 75 mg BID During Primary Assessment Period", "description": "Following the Primary Assessment Period, subjects were followed within their randomized treatment group", "deathsNumAffected": 0, "deathsNumAtRisk": 24, "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 5, "otherNumAtRisk": 24}, {"id": "EG008", "title": "Eosinophil Recovery Period: Assigned to 150 mg BID During Primary Assessment Period", "description": "Following the Primary Assessment Period, subjects were followed within their randomized treatment group", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 10, "otherNumAtRisk": 28}], "otherEvents": [{"term": "Monocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Sinus Bradycardia", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Aphthous ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Corona virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Ear infection fungal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Otitis externa", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Urethritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Foreign body in ear", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Scratch", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Sunburn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Coronavirus test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Muscle twitching", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Eye contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Soft tissue injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Hypomagnesaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Knopp's agreements with its investigators may vary. However, Knopp does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial, and are subject to a minimum 60 day review period by Knopp."}, "pointOfContact": {"title": "Vice President, Clinical and Translational Medicine", "organization": "Knopp Biosciences", "email": "calman@knoppbio.com", "phone": "4124881776"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-07-16", "uploadDate": "2021-11-23T16:42", "filename": "Prot_000.pdf", "size": 15354971}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-12-22", "uploadDate": "2021-11-23T16:53", "filename": "SAP_001.pdf", "size": 1779855}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000011657", "term": "Pulmonary Eosinophilia"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000017681", "term": "Hypereosinophilic Syndrome"}, {"id": "D000004802", "term": "Eosinophilia"}, {"id": "D000007960", "term": "Leukocyte Disorders"}, {"id": "D000006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "asFound": "Eosinophilic Asthma", "relevance": "HIGH"}, {"id": "M7961", "name": "Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M19901", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}, {"id": "M10963", "name": "Leukocyte Disorders", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "T2886", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077487", "term": "Pramipexole"}, {"id": "D000097662", "term": "Dexpramipexole"}], "ancestors": [{"id": "D000000975", "term": "Antioxidants"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000000978", "term": "Antiparkinson Agents"}, {"id": "D000018726", "term": "Anti-Dyskinesia Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}], "browseLeaves": [{"id": "M1813", "name": "Pramipexole", "asFound": "NGAL", "relevance": "HIGH"}, {"id": "M3373", "name": "Dexpramipexole", "asFound": "NGAL", "relevance": "HIGH"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4295", "name": "Antiparkinson Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnDyAg", "name": "Anti-Dyskinesia Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}